Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German study rejects neuroblastoma screening

This article was originally published in Clinica

Executive Summary

A mass early-detection programme for neuroblastoma, a form of cancer, in children aged 10-12 months serves no purpose, claims a recent German report published earlier this month in the New England Journal of Medicine. Speaking at a conference in Bonn last week, Dr Freimut Schilling from the Olga Hospital in Stuttgart, secretary of the German model project for neuroblastoma early-detection, said that such screening was pointless as it neither reduced the number of deaths, nor the number of children reaching the advanced stage of the illness.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT066032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel